Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

Research output: Contribution to journalArticle

Bibtex

@article{ff19abeaa2384878b292ccf4c9c990ca,
title = "Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)",
abstract = "The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0{\%} men, 56.8{\%} women) and 136 to glimepiride (54.0{\%} men, 43.2{\%} women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8{\%}; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.",
keywords = "IFG, prevention, primary care, randomized trial, sulphonylurea, type 2, diabetes",
author = "U. Lindblad and Gunnar Lindberg and Nils-Ove M{\aa}nsson and Jonas Ranstam and Maria Tyrberg and S. Jansson and K. Lindwall and Mona Sv{\"a}rdh and L. Kindmalm and Arne Melander",
year = "2011",
doi = "10.1111/j.1463-1326.2010.01331.x",
language = "English",
volume = "13",
pages = "185--188",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "2",

}